- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe-10-01-2008
Pharmaceutical Technology Europe
It's a small world
October 01, 2008
Spotlight
20
10
In the popular view of nanomedicine, miniature robots equipped with a set of tools will one day patrol the inside of the body, cleaning up atheroslerotic plaque, zapping cancer cells, and generally performing repair and maintenance.
Monitoring dissolved ozone in the pharmaceutical industry
October 01, 2008
Analytical Equipment
20
10
Emerging technologies now enable continuous on-line monitoring and control of ozone systems, providing precise and reliable results, revolutionizing the way dissolved ozone is measured.
Quality by Design for analytical methods for use with orally inhaled and nasal drug products
October 01, 2008
Drug Delivery
20
10
The design of accurate and robust analytical methodology is instrumental to developing orally inhaled and nasal drug products (OINDPs) and their appropriate control programmes.
PAT — a team effort
October 01, 2008
PAT
20
10
The biggest benefit of PAT and the current FDA initiatives may be in allowing pharmaceutical scientists to use their technical capabilities to improve pharmaceutical processes.
Power to the people
October 01, 2008
Viewpoint
20
10
The most public argument against direct-to-consumer advertising in Europe is essentially paternalistic: to protect people from companies who are considered unable to present an objective account of their drugs.
Pushing for allergen labelling
October 01, 2008
Pushing for allergen labelling
20
10
The biggest benefit that has been brought about by the compulsory labelling of allergens in food is the greater degree of cooperation that has been established between food manufacturers and their suppliers.
Small company, big career
October 01, 2008
Business
20
10
The days of a 'job for life' at a Big Pharma company seem to be well behind us, whether we're at the bench or in the boardroom, but that doesn't mean we should view the employment landscape with trepidation.
A future without "grey goo"
October 01, 2008
20th Anniversary Special feature
20
10
Nanoparticles can also cross the blood–brain barrier, which could make them useful for delivering drugs that target brain tumours or diseases that affect the central nervous system.
Business suicide?
October 01, 2008
20
10
Counterfeiting has become the topic of conversation at all levels of the pharmaceutical industry. Considering the rising number of cases, this is hardly surprising.
Let's talk the same language
October 01, 2008
Talking Point
20
10
The potent nature of HPAPIs means there must be careful evaluation of the compound for its level of toxicity when considering manufacture.
PVA copolymer: the new coating agent
October 01, 2008
Formulation
20
10
The use of PVA copolymer-based film can solve the problems associated with lack of film adhesion... to tablets containing large amounts of waxy excipient or a lubricant.
Successful strategies for product optimization
October 01, 2008
Biopharmaceuticals
20
10
...an uninformed decision based on commercial requirements alone may, ultimately, have disastrous consequences on the efficacy of the target recombinants.
CMOs must face new realities
October 01, 2008
Outsourcing review
20
10
CMOs must find new business models and strategies that reflect the many dimensions of the industry's realities...